Bejelentkezés Regisztrálj ingyen

Kazia Therapeutics jövedelem

Mi az Kazia Therapeutics jövedelem?

A jövedelem az Kazia Therapeutics Limited - AUD$10.000k

Mi a jövedelem meghatározása?



A bevétel olyan jövedelem, amelyet a vállalkozásnak szokásos üzleti tevékenységéből származik, általában az áruk és szolgáltatások ügyfeleknek történő értékesítéséből.

Revenue is also referred to as sales or turnover. Some companies receive revenue from interest, royalties, or other fees. Revenue may refer to business income in general, or it may refer to the amount, in a monetary unit, earned during a period of time, as in "Last year, Company X had revenue of $42 million". Profits or net income generally imply total revenue minus total expenses in a given period.

In accounting, revenue is often referred to as the "top line" due to its position on the income statement at the very top. This is to be contrasted with the "bottom line" which denotes net income.

jövedelem a Health Care szektor a ASX-on cégekben a Kazia Therapeutics -hoz képest

Mit csinál Kazia Therapeutics?

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

jövedelem -hoz hasonló cégek Kazia Therapeutics